Investment Thesis
Foghorn is an early-stage biotech with negative stockholders equity (-$76.4M) and devastating operating losses (-660% margin), indicating severe financial distress. Despite revenue growth of 36.8% YoY and improving EPS, the company burns $25.3M annually with only 3.5 years of cash runway at current rates, raising significant concerns about long-term viability without transformative clinical success.
Strengths
- Strong cash position of $87.7M provides near-term operational runway
- Revenue growing 36.8% year-over-year and EPS improving (losses narrowing by 25.3% YoY)
- No long-term debt burden reduces financial obligations and refinancing risk
Risks
- Negative stockholders equity of -$76.4M indicates liabilities exceed assets, signaling financial distress and high dilution risk
- Unsustainable cash burn rate of $25.3M annually against only $3.3M revenue with ~3.5 years of runway remaining
- Operating margins of -660% and net margins of -608% demonstrate the business model is not economically viable at current stage
Key Metrics to Watch
- Quarterly revenue growth trajectory and inflection toward positive gross margin
- Monthly cash burn rate and revised cash runway estimates
- Clinical pipeline advancement, trial enrollment, and FDA milestone achievements
Financial Metrics
Revenue
3.3M
Net Income
-19.9M
EPS (Diluted)
$-0.29
Free Cash Flow
-25.3M
Total Assets
222.2M
Cash
87.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-660.3%
Net Margin
-608.4%
ROE
N/A
ROA
-8.9%
FCF Margin
-773.4%
Balance Sheet & Liquidity
Current Ratio
2.92x
Quick Ratio
2.92x
Debt/Equity
N/A
Debt/Assets
134.4%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:20:34.216280 |
Data as of: 2026-03-31 |
Powered by Claude AI